Do prognosis and clinicopathological features differ in young early-stage breast cancer?
age factors
breast cancer
cancer-specific survival
disease-free survival
early stage
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
03
2022
accepted:
21
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Breast cancer is the most frequently detected cancer and the leading cause of cancer-related death in women. Although it is mostly seen in older patients, breast cancer affects women aged 24 to >70 years, with poorer prognosis in young patients. Young age remains a controversial topic in the literature. This study aimed to identify subtype differences and the effect of age on early-stage breast cancer outcomes. A total of 300 consecutive patients underwent surgery between 2011 and 2015 for early-stage breast cancer. Of these, 248 were eligible for this study and were divided into three groups: group Y (aged ≤35 years), group M (aged >35 and ≤45 years), and group E (aged >45 years). The clinical and pathological features and data related to recurrence, metastasis, and death were recorded. No statistical differences were found between groups regarding histopathological features except for higher histological grade and Ki-67 levels in group M. Additionally, group Y recorded no progression (recurrence or metastasis) or death. Disease-free survival was 117.8 months (95% CI 111.8-123.8) for group M, which was significantly shorter than that for group E ( A very young age cannot be considered an independent risk factor for poor prognosis. Rather than age, histological grade and Ki-67 index are more important factors in early-stage breast cancer.
Sections du résumé
Background
UNASSIGNED
Breast cancer is the most frequently detected cancer and the leading cause of cancer-related death in women. Although it is mostly seen in older patients, breast cancer affects women aged 24 to >70 years, with poorer prognosis in young patients. Young age remains a controversial topic in the literature. This study aimed to identify subtype differences and the effect of age on early-stage breast cancer outcomes.
Methods
UNASSIGNED
A total of 300 consecutive patients underwent surgery between 2011 and 2015 for early-stage breast cancer. Of these, 248 were eligible for this study and were divided into three groups: group Y (aged ≤35 years), group M (aged >35 and ≤45 years), and group E (aged >45 years). The clinical and pathological features and data related to recurrence, metastasis, and death were recorded.
Results
UNASSIGNED
No statistical differences were found between groups regarding histopathological features except for higher histological grade and Ki-67 levels in group M. Additionally, group Y recorded no progression (recurrence or metastasis) or death. Disease-free survival was 117.8 months (95% CI 111.8-123.8) for group M, which was significantly shorter than that for group E (
Conclusion
UNASSIGNED
A very young age cannot be considered an independent risk factor for poor prognosis. Rather than age, histological grade and Ki-67 index are more important factors in early-stage breast cancer.
Identifiants
pubmed: 36338611
doi: 10.3389/fsurg.2022.900363
pmc: PMC9629693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
900363Informations de copyright
© 2022 Arikan, Kara, Dülgeroğlu, Erdoğan, Çapkınoğlu and Uras.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Glob Oncol. 2019 Nov;5:1-10
pubmed: 31730380
Breast Cancer Res Treat. 2012 Feb;131(3):1061-6
pubmed: 22080245
J Clin Oncol. 2016 Sep 20;34(27):3308-14
pubmed: 27480155
Adv Anat Pathol. 2020 Jan;27(1):27-35
pubmed: 31045583
World J Surg. 2011 Jun;35(6):1244-53
pubmed: 21472372
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer Manag Res. 2021 Feb 17;13:1601-1607
pubmed: 33628050
Breast. 2013 Dec;22(6):1046-51
pubmed: 24091127
Int J Clin Exp Med. 2015 Apr 15;8(4):5869-75
pubmed: 26131178
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
J Adolesc Young Adult Oncol. 2019 Oct;8(5):628-634
pubmed: 31259658
BMC Cancer. 2022 Jan 3;22(1):27
pubmed: 34980002
Cancer Res Treat. 2017 Apr;49(2):484-493
pubmed: 27554479
Asian Pac J Cancer Prev. 2013;14(10):5949-52
pubmed: 24289606
Biomed Res Int. 2015;2015:325715
pubmed: 26351632
Breast Cancer Res Treat. 2019 Oct;177(3):713-722
pubmed: 31297648
Breast. 2015 Nov;24 Suppl 2:S154-8
pubmed: 26255745
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Front Oncol. 2020 Sep 23;10:1729
pubmed: 33072554
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
Br J Cancer. 1996 Dec;74(11):1796-800
pubmed: 8956795
Breast. 2016 Oct;29:109-16
pubmed: 27479041